[
  {
    "ts": null,
    "headline": "Lilly IBD biologic receives expanded US approval",
    "summary": "The US Food and Drug Administration has approved Omvoh ® for moderately to severely active Crohn’s disease in US adults. The biologic was authorised in the US as a first-in-class therapy for...",
    "url": "https://finnhub.io/api/news?id=3dc34b475d502b177224e6be9d758c2ab9b198acf40dadadde336fb5dad7785f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737025272,
      "headline": "Lilly IBD biologic receives expanded US approval",
      "id": 132406371,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "The US Food and Drug Administration has approved Omvoh ® for moderately to severely active Crohn’s disease in US adults. The biologic was authorised in the US as a first-in-class therapy for...",
      "url": "https://finnhub.io/api/news?id=3dc34b475d502b177224e6be9d758c2ab9b198acf40dadadde336fb5dad7785f"
    }
  },
  {
    "ts": null,
    "headline": "Finally An Attractive Entry Point Into Novo Nordisk",
    "summary": "Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%.",
    "url": "https://finnhub.io/api/news?id=96dbaef748aa42cc8684a23308bf03ddf2d06ea3f4e4861125d645555fac6eb5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737014178,
      "headline": "Finally An Attractive Entry Point Into Novo Nordisk",
      "id": 132405497,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153927815/image_2153927815.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%.",
      "url": "https://finnhub.io/api/news?id=96dbaef748aa42cc8684a23308bf03ddf2d06ea3f4e4861125d645555fac6eb5"
    }
  },
  {
    "ts": null,
    "headline": "Next Century Growth Investors Q4 2024 Commentary",
    "summary": "In the fourth quarter of 2024, equity markets were positive and large cap stocks generally outperformed small cap stocks. Read more here.",
    "url": "https://finnhub.io/api/news?id=73e8069e54636e4d13a9d94bc0d115cbdc6cab07173db678464c129ad714ba43",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737008700,
      "headline": "Next Century Growth Investors Q4 2024 Commentary",
      "id": 132404982,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1305707642/image_1305707642.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "In the fourth quarter of 2024, equity markets were positive and large cap stocks generally outperformed small cap stocks. Read more here.",
      "url": "https://finnhub.io/api/news?id=73e8069e54636e4d13a9d94bc0d115cbdc6cab07173db678464c129ad714ba43"
    }
  },
  {
    "ts": null,
    "headline": "Tempering Positive Sentiment Of AI In Biotech",
    "summary": "AI optimizes existing knowledge but doesn't expedite drug approval or reduce costs compared to traditional methods. Explore more details here.",
    "url": "https://finnhub.io/api/news?id=cd2ce10465b2022ad38901994024c990f366b0e2333aac6670be174216a19808",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737007436,
      "headline": "Tempering Positive Sentiment Of AI In Biotech",
      "id": 132404884,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2163707266/image_2163707266.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "AI optimizes existing knowledge but doesn't expedite drug approval or reduce costs compared to traditional methods. Explore more details here.",
      "url": "https://finnhub.io/api/news?id=cd2ce10465b2022ad38901994024c990f366b0e2333aac6670be174216a19808"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: FDA approves Omvoh for Crohn's disease",
    "summary": "Eli Lilly announces that the US Food and Drug Administration has approved Omvoh for the treatment of moderate to severe Crohn's disease in adults. Already approved in 2023 for ulcerative colitis,...",
    "url": "https://finnhub.io/api/news?id=3e0877ffc5aff3a2b400c457f896b759f5dbcd6da4f05c5d8c9a3a0643cb1485",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736999776,
      "headline": "Eli Lilly: FDA approves Omvoh for Crohn's disease",
      "id": 132404193,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly announces that the US Food and Drug Administration has approved Omvoh for the treatment of moderate to severe Crohn's disease in adults. Already approved in 2023 for ulcerative colitis,...",
      "url": "https://finnhub.io/api/news?id=3e0877ffc5aff3a2b400c457f896b759f5dbcd6da4f05c5d8c9a3a0643cb1485"
    }
  }
]